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1. INTRODUCTION {#cam43110-sec-0005}
===============

Following completion of treatment for childhood malignancy, regular imaging studies are frequently used alongside clinical review to assess for recurrence of disease.[^1^](#cam43110-bib-0001){ref-type="ref"} It is anticipated that imaging may identify relapse before signs and symptoms develop, allowing earlier or less intensive treatment with an increased chance of survival.[^2^](#cam43110-bib-0002){ref-type="ref"}

However, there has been some suggestion that this is not the case, as recurrence may still be detected clinically, and detection via imaging may not increase overall survival.[^1^](#cam43110-bib-0001){ref-type="ref"}, [^3^](#cam43110-bib-0003){ref-type="ref"}, [^4^](#cam43110-bib-0004){ref-type="ref"} Surveillance imaging comes with costs, including a psychological burden on families, possible increased risk of second malignancy, incidental findings, and increased exposure to general anesthesia, along with financial and opportunity costs to health services.[^2^](#cam43110-bib-0002){ref-type="ref"}, [^4^](#cam43110-bib-0004){ref-type="ref"}

This systematic review seeks to establish if routine surveillance imaging after treatment of pediatric extracranial solid tumors causes more harm than good, specifically examining the impact on overall survival, anxiety and other psychological distress, number of scans received, radiation dose, other harms of surveillance, and cost‐effectiveness.

2. METHODS {#cam43110-sec-0006}
==========

The review protocol was prospectively registered on PROSPERO (CRD42018103764) and published.[^5^](#cam43110-bib-0005){ref-type="ref"}

2.1. Patient and public involvement {#cam43110-sec-0007}
-----------------------------------

A patient and public involvement (PPI) group steered the review from the outset, ranking important outcomes, understanding the context and implications of the results, including further research needs, and active involvement in the dissemination of the research. A young person with experience of childhood cancer summarized the review to be accessible to high‐school students (Supplemental File [1](#cam43110-sup-0001){ref-type="supplementary-material"}).

2.2. Searches {#cam43110-sec-0008}
-------------

Electronic searches were undertaken from 1990 onwards, reflecting the current era of survival in childhood cancer. Published and unpublished studies were sought and no language or study design restrictions were applied, as such randomized controlled trials, quasi‐randomized studies, prospective, and retrospective cohort studies were all eligible to be included, as described in the protocol.[^5^](#cam43110-bib-0005){ref-type="ref"} The following databases were searched in July 2018: MEDLINE (Epub Ahead of Print, In‐Process & Other Non‐Indexed Citations, Ovid MEDLINE Daily, and Ovid MEDLINE), PubMed, EMBASE, PsycINFO, Cumulative Index to Nursing & Allied Health (CINAHL Plus), Science Citation Index, Conference Proceedings Citation Index---Science, Cochrane Database of Systematic Reviews (CDSR), Cochrane Central Register of Controlled Trials (CENTRAL), Health Technology Assessment (HTA) database, Database of Abstracts of Reviews of Effects (DARE), NHS Economic Evaluation Database (NHS EED), PROSPERO, and EconLit. (Supplemental File [2](#cam43110-sup-0002){ref-type="supplementary-material"}). Searches of conference proceedings of the RCPCH (Royal College of Paediatrics and Child Health), SIOP (International Society of Paediatric Oncology), ASPHO (American Society of Paediatric Hematology/Oncology), ASCO (American Society of Clinical Oncology), and ASH (American Society of Hematology), along with ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform portal were undertaken. Reference lists of relevant systematic reviews and included articles were reviewed and forward citation searching of included articles was performed, using Web of Science.

2.3. Screening and data extraction {#cam43110-sec-0009}
----------------------------------

For inclusion and exclusion criteria see Box [1](#cam43110-fea-0001){ref-type="boxed-text"}. Two authors independently screened the title and abstract of studies, dual‐screening 10% of the records and single‐screening the remaining 90% as agreement was good (96.6%). Disagreements were resolved by consensus, or by recourse to a third author. Data extraction was performed by two authors. Study quality was assessed using a modified ROBINS‐I tool, supplemented with potential sources of heterogeneity: patient demographic and clinical characteristics, study era, and geography.[^6^](#cam43110-bib-0006){ref-type="ref"}, [^7^](#cam43110-bib-0007){ref-type="ref"}

###### Study inclusion and exclusion criteria

###  {#cam43110-sec-0010}

Inclusion criteria: ‐Population: Children or young people up to 25 years who had completed treatment for a malignant extracranial solid tumour and had no evidence of active and ongoing disease at end of treatment (or results for this subgroup)‐Intervention: programme of surveillance imaging aiming to detect relapse of previously treated childhood cancer‐Comparators: routine clinical review, another surveillance programme (using imaging or laboratory measures) or none (some studies reported this comparison as detection of relapses by surveillance compared to by symptoms)

Outcomes: Primary: Overall Survival (age at time of death or time from original diagnosis)Secondary: psychological distress indicators, number of imaging tests, cost‐effectiveness, qualitative data relating to experiences of surveillance imaging, other harms of imaging (as identified by the studies themselves)

Exclusion criteria ‐Case studies‐Studies from Low and Middle‐Income Countries (LMIC) ‐ Only studies performed in high‐income countries were included, to reflect the treatment and surveillance strategies in these settings.‐Surveillance solely related to patients with cancer predisposition syndromes‐Surveillance looking predominantly for late effects of treatment

2.4. Analysis {#cam43110-sec-0011}
-------------

Key study characteristics were summarized in narrative and tabular forms. Given the degree of clinical heterogeneity and absence of sufficient data, meta‐analysis was not appropriate. Narrative synthesis was performed by tumor type, and focused on the key themes of: method of identification of relapse, burden of surveillance programs, and effects on survival.

3. RESULTS {#cam43110-sec-0012}
==========

About 17 727 unique records were identified by the search, 17 226 were excluded on title and abstract, and 449 excluded following full‐text review (Figure [1](#cam43110-fig-0001){ref-type="fig"}). Review of conference proceedings and references searches identified three further studies. Review of trial registries identified no ongoing relevant studies.

![Flow diagram for study selection](CAM4-9-4949-g001){#cam43110-fig-0001}

3.1. Mapping summary {#cam43110-sec-0013}
--------------------

Fifty‐five studies, with 10 423 participants, were included (Table [1](#cam43110-tbl-0001){ref-type="table"}). Most (48/55) studies were retrospective cohort studies. Twelve studies reported "mixed malignancies" where patients with more than one type of malignancy were included, including mixed lymphomas.[^1^](#cam43110-bib-0001){ref-type="ref"}, [^8^](#cam43110-bib-0008){ref-type="ref"}, [^9^](#cam43110-bib-0009){ref-type="ref"}, [^10^](#cam43110-bib-0010){ref-type="ref"}, [^11^](#cam43110-bib-0011){ref-type="ref"}, [^12^](#cam43110-bib-0012){ref-type="ref"}, [^13^](#cam43110-bib-0013){ref-type="ref"}, [^14^](#cam43110-bib-0014){ref-type="ref"}, [^15^](#cam43110-bib-0015){ref-type="ref"}, [^16^](#cam43110-bib-0016){ref-type="ref"}, [^17^](#cam43110-bib-0017){ref-type="ref"}, [^18^](#cam43110-bib-0018){ref-type="ref"} These studies do not provide sufficient granularity to advise clinical decision‐making and as such are not discussed further in this paper, information relating to these are provided in Supplemental File [3](#cam43110-sup-0003){ref-type="supplementary-material"}. Wilms tumor was the most frequently studied malignancy. Surveillance programs were poorly reported. Eight main imaging modalities were assessed (CT, gallium scan, ultrasound, X‐ray, MRI, FDG‐PT, bone scan, and MIBG), with most studies (32/55) assessing more than one modality and CT most commonly used (32/55 studies). In many studies, it was unclear whether surveillance imaging was within a clinical trial or part of routine care.

###### 

Study characteristics

  Study                                                    Year of publication   Disease                           Country                                                            N participants   N participants experiencing relapse   Age (median^1^, mean^2^)   Details of surveillance program                                                                     
  -------------------------------------------------------- --------------------- --------------------------------- ------------------------------------------------------------------ ---------------- ------------------------------------- -------------------------- -------------------------------------------- ------------------------------------------------------ -------
  Bayar[^19^](#cam43110-bib-0019){ref-type="ref"}          2000                  NHL                               US                                                                 44               0                                     8.33^2^                    CT, Gallium scans                            3‐6 mo                                                 6
  Borst[^20^](#cam43110-bib-0020){ref-type="ref"}          2013                  NHL                               US                                                                 12               0                                     12.42^2^                   CT, Gallium scans, MRI, FDG‐PET, Bone scan   Every 3 mo for 12‐24 mo, decreasing with time          10
  Eissa[^21^](#cam43110-bib-0021){ref-type="ref"}          2014                  NHL                               US                                                                 44               3                                     8.88^2^                    CT, Gallium scans, X‐ray, FDG‐PET            NR                                                     10
  Karantanis[^22^](#cam43110-bib-0022){ref-type="ref"}     2010                  NHL                               US                                                                 10               0                                     36.1^2^                    CT, FDG‐PET                                  NR                                                     NR
  Friedmann[^23^](#cam43110-bib-0023){ref-type="ref"}      2013                  Hodgkin\'s lymphoma               US                                                                 402              64                                    15.6^1^                    CT, Gallium scans, X‐ray, FDG‐PET            Every 3 mo for 1 y, decreasing with time               18.3
  Levine[^24^](#cam43110-bib-0024){ref-type="ref"}         2006                  Hodgkin\'s lymphoma               US                                                                 47               3                                     15^1^                      CT, FDG‐PET                                  NR                                                     5
  Meany[^25^](#cam43110-bib-0025){ref-type="ref"}          2007                  Hodgkin\'s lymphoma               US                                                                 25               2                                     14.2^2^                    CT, FDG‐PET                                  Every 3 mo for 2 y                                     3.83
  Voss[^26^](#cam43110-bib-0026){ref-type="ref"}           2012                  Hodgkin\'s lymphoma               US                                                                 219              25                                    NR                         CT, Gallium scans                            NR                                                     NR
  Wickmann[^27^](#cam43110-bib-0027){ref-type="ref"}       2003                  Hodgkin\'s lymphoma               Germany                                                            15               13                                    NR                         CT, MRI, FDG‐PET                             Every 6 mo, decreasing with time                       NR
  Chang[^31^](#cam43110-bib-0031){ref-type="ref"}          2015                  Osteosarcoma                      South Korea                                                        153              9                                     17^2^                      FDG‐PET                                      Every 3‐6 mo for 2 y, decreasing with time             7.67
  Korholz[^28^](#cam43110-bib-0028){ref-type="ref"}        1998                  Osteosarcoma                      Germany                                                            78               28                                    14^1^                      CT, X‐ray, Bone scan, Other                  Every 3‐6 mo for 1‐2 y, decreasing with time           15.11
  Korholz[^29^](#cam43110-bib-0029){ref-type="ref"}        1996                  Osteosarcoma                      Germany                                                            78               28                                    14^1^                      CT, X‐ray, Bone scan,                        Monthly or bimonthly for 1‐2 y, decreasing with time   NR
  Massera[^32^](#cam43110-bib-0032){ref-type="ref"}        1994                  Osteosarcoma                      Italy                                                              16               6                                     19^2^                      CT                                           NR                                                     NR
  Korholz[^30^](#cam43110-bib-0030){ref-type="ref"}        2000                  Osteosarcoma & Ewing\'s sarcoma   Germany                                                            119              7                                     15^1^                      CT, X‐ray, Bone scan,                        NR                                                     14
  Cash[^33^](#cam43110-bib-0033){ref-type="ref"}           2013                  Ewing\'s sarcoma                  US                                                                 71               21                                    NR                         NR                                           NR                                                     NR
  Heinemann[^34^](#cam43110-bib-0034){ref-type="ref"}      2018                  Ewing\'s sarcoma                  Germany                                                            180              30                                    13.8^1^                    CT, X‐ray, MRI, FDG‐PET, Bone scan           Every 1.5 and 3 mo for 1 y, decreasing with time       5
  Heinemann[^35^](#cam43110-bib-0035){ref-type="ref"}      2017                  Ewing\'s sarcoma                  Germany                                                            284              160                                   15^1^                      CT, X‐ray, FDG‐PET, Bone scan                Every 1.5 and 3 mo for 1 y, decreasing with time       12
  Brok[^36^](#cam43110-bib-0036){ref-type="ref"}           2018                  Wilms tumor                       Brazil, France, Germany, Netherlands, UK                           4271             538                                   4.22^1^                    Ultrasound, X‐ray                            Every 3 monthly for 12‐24 mo, decreasing with time     10
  Carrico[^37^](#cam43110-bib-0037){ref-type="ref"}        1997                  Wilms tumor                       US                                                                 60               7                                     3.5^2^                     Ultrasound, X‐ray                            Between 6 wks and 3 mo, variable on disease stage      5
  Daw[^38^](#cam43110-bib-0038){ref-type="ref"}            2002                  Wilms tumor                       US                                                                 280              8                                     30^1^                      CT, Ultrasound                               NR                                                     NR
  Kaste[^39^](#cam43110-bib-0039){ref-type="ref"}          2013                  Wilms tumor                       US                                                                 110              16                                    2.92^1^                    CT                                           NR                                                     NR
  Mullen[^40^](#cam43110-bib-0040){ref-type="ref"}         2018                  Wilms tumor                       US, Canada, Australia, New Zealand, Switzerland, and Netherlands   336              281                                   NR                         CT, Ultrasound, X‐ray                        NR                                                     NR
  Davini[^41^](#cam43110-bib-0041){ref-type="ref"}         2018                  Hepatoblastoma                    US                                                                 31               NR                                    NR                         CT                                           NR                                                     NR
  Rojas[^42^](#cam43110-bib-0042){ref-type="ref"}          2014                  Hepatoblastoma                    US                                                                 26               5                                     2.33^2^                    CT, Ultrasound, MRI, FDG‐PET                 Every 3 mo for 1 y, then at discretion of oncologist   NR
  Bruggers[^43^](#cam43110-bib-0043){ref-type="ref"}       1998                  Neuroblastoma                     US                                                                 32               22                                    3.75^2^                    NR                                           NR                                                     NR
  Federico[^44^](#cam43110-bib-0044){ref-type="ref"}       2015                  Neuroblastoma                     US                                                                 78               46                                    2.7^1^                     CT, MIBG                                     NR                                                     NR
  Kushner[^45^](#cam43110-bib-0045){ref-type="ref"}        2009                  Neuroblastoma                     US                                                                 154              154                                   NR                         CT, MIBG                                     Every 2 to 4 months                                    NR
  Okuyama[^46^](#cam43110-bib-0046){ref-type="ref"}        2002                  Neuroblastoma                     Japan                                                              40               5                                     1.2^1^                     MIBG                                         Every 3‐12 mo, variable with disease stage             NR
  Owens[^47^](#cam43110-bib-0047){ref-type="ref"}          2016                  Neuroblastoma                     Canada                                                             183              50                                    3.54^1^                    MRI, MIBG                                    NR                                                     NR
  Cogswell[^50^](#cam43110-bib-0050){ref-type="ref"}       1994                  Rhabdomyosarcoma                  Australia                                                          40               10                                    5.83^1^                    Gallium scans, X‐ray, Bone scan              Every 3 mo for 2 y, decreasing with time               NR
  Lin[^3^](#cam43110-bib-0003){ref-type="ref"}             2016                  Rhabdomyosarcoma                  US                                                                 145              24                                    13.5^2^                    NR                                           NR                                                     NR
  Mallebranche[^52^](#cam43110-bib-0052){ref-type="ref"}   2017                  Rhabdomyosarcoma                  France                                                             99               NR                                    5^1^                       Ultrasound, X‐ray                            Every 2 mo for 2 y, decreasing with time               NR
  Vaarwerk[^51^](#cam43110-bib-0051){ref-type="ref"}       2018                  Rhabdomyosarcoma                  UK                                                                 182              182                                   NR                         NR                                           NR                                                     17.7
  Sirin[^48^](#cam43110-bib-0048){ref-type="ref"}          2016                  Retinoblastoma                    Germany                                                            50               3                                     1.17^2^                    MRI                                          NR                                                     6
  White[^49^](#cam43110-bib-0049){ref-type="ref"}          1991                  Retinoblastoma                    Australia, US                                                      15               0                                     21^2^                      Bone scan                                    Every 4 mo, decreasing with time                       5
  Lobeck[^53^](#cam43110-bib-0053){ref-type="ref"}         2017                  Appendiceal carcinoid tumors      US                                                                 30               0                                     13.5^2^                    CT, Ultrasound, MRI                          NR                                                     5.33
  Geldart[^54^](#cam43110-bib-0054){ref-type="ref"}        2006                  Germ cell tumor                   UK                                                                 329              20                                    23^1^                      NR                                           NR                                                     NR
  Halalsheh[^55^](#cam43110-bib-0055){ref-type="ref"}      2018                  Malignant melanoma                US                                                                 21               4                                     14.0^1^                    MRI/CT, PET/CT                               Every 6 mo                                             
  Cheuk[^56^](#cam43110-bib-0056){ref-type="ref"}          2012                  Nasopharyngeal carcinoma          US                                                                 18               1                                     13.6^1^                    MRI, FDG‐PET                                 NR                                                     NR
  Zanetta[^57^](#cam43110-bib-0057){ref-type="ref"}        1994                  Ovarian cancer                    Italy                                                              106              9                                     NR                         Ultrasound                                   Every 3 mo, decreasing with time                       NR
  Laddie[^58^](#cam43110-bib-0058){ref-type="ref"}         2009                  Testicular tumor                  UK                                                                 51               12                                    NR                         CT                                           NR                                                     NR
  Vali[^59^](#cam43110-bib-0059){ref-type="ref"}           2015                  Thyroid cancer                    Canada                                                             54               17                                    14.1^2^                    Ultrasound                                   Every 6‐12 mo                                          10
  Berrettini[^60^](#cam43110-bib-0060){ref-type="ref"}     2015                  Urothelial bladder neoplasms      UK                                                                 18               0                                     11^1^                      Ultrasound                                   Varied per center                                      14.5

Abbreviations: NHL, Non‐Hodgkin's lymphoma; NR, not reported; UK, United Kingdom; US, United States.
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3.2. Risk of bias {#cam43110-sec-0014}
-----------------

Risk of bias was variable, with most studies demonstrating moderate to serious risk of bias (Table [2](#cam43110-tbl-0002){ref-type="table"}). Particular issues relate to confounding and lead‐time bias (where studies measure survival from time of detection of relapse, rather than from original diagnosis).

###### 

Risk of bias for studies

  Study                                                    Year   Confounding   Patient selection   Protocol deviation   Missing data   Knowledge of intervention and recording of outcome   Effect estimate   Overall judgment of risk
  -------------------------------------------------------- ------ ------------- ------------------- -------------------- -------------- ---------------------------------------------------- ----------------- --------------------------
  Bayar[^19^](#cam43110-bib-0019){ref-type="ref"}          2000                                                                                                                                                Moderate
  Berrettini[^60^](#cam43110-bib-0060){ref-type="ref"}     2015                                                                                                                                                Moderate
  Borst[^20^](#cam43110-bib-0020){ref-type="ref"}          2013                                                                                                                                                Moderate
  Brok[^36^](#cam43110-bib-0036){ref-type="ref"}           2018                                                                                                                                                Serious
  Bruggers[^43^](#cam43110-bib-0043){ref-type="ref"}       1998                                                                                                                                                Moderate
  Carrico[^37^](#cam43110-bib-0037){ref-type="ref"}        1997                                                                                                                              Low               
  Cash[^33^](#cam43110-bib-0033){ref-type="ref"}           2013                                                                                                                                                Moderate
  Chang[^31^](#cam43110-bib-0031){ref-type="ref"}          2015                                                                                                                                                Moderate
  Cheuk[^56^](#cam43110-bib-0056){ref-type="ref"}          2012                                                                                                                                                Moderate
  Cogswell[^50^](#cam43110-bib-0050){ref-type="ref"}       1994                                                                                                                                                Moderate
  Davini[^41^](#cam43110-bib-0041){ref-type="ref"}         2018                                                                                                                                                Moderate
  Daw[^38^](#cam43110-bib-0038){ref-type="ref"}            2002                                                                                                                                                Moderate
  Eissa[^21^](#cam43110-bib-0021){ref-type="ref"}          2014                                                                                                                                                Moderate
  Federico[^44^](#cam43110-bib-0044){ref-type="ref"}       2015                                                                                                                                                Moderate
  Friedmann[^23^](#cam43110-bib-0023){ref-type="ref"}      2013                                                                                                                                                Serious
  Geldart[^54^](#cam43110-bib-0054){ref-type="ref"}        2006                                                                                                                                                Serious
  Halalsheh[^55^](#cam43110-bib-0055){ref-type="ref"}      2018                                                                                                                                                Moderate
  Heinemann[^34^](#cam43110-bib-0034){ref-type="ref"}      2018                                                                                                                                                Moderate
  Heinemann[^35^](#cam43110-bib-0035){ref-type="ref"}      2017                                                                                                                                                Serious
  Karantanis[^22^](#cam43110-bib-0022){ref-type="ref"}     2010                                                                                                                                                Moderate
  Kaste[^39^](#cam43110-bib-0039){ref-type="ref"}          2013                                                                                                                                                Moderate
  Korholz[^28^](#cam43110-bib-0028){ref-type="ref"}        1998                                                                                                                                                Moderate
  Korholz[^29^](#cam43110-bib-0029){ref-type="ref"}        1996                                                                                                                                                Serious
  Korholz[^30^](#cam43110-bib-0030){ref-type="ref"}        2000                                                                                                                                                Serious
  Kushner[^45^](#cam43110-bib-0045){ref-type="ref"}        2009                                                                                                                                                Serious
  Laddie[^58^](#cam43110-bib-0058){ref-type="ref"}         2009                                                                                                                                                Moderate
  Levine[^24^](#cam43110-bib-0024){ref-type="ref"}         2006                                                                                                                                                Moderate
  Lin[^3^](#cam43110-bib-0003){ref-type="ref"}             2016                                                                                                                                                Moderate
  Lobeck[^53^](#cam43110-bib-0053){ref-type="ref"}         2017                                                                                                                                                Moderate
  Mallebranche[^52^](#cam43110-bib-0052){ref-type="ref"}   2017                                                                                                                                                Critical
  Massera[^32^](#cam43110-bib-0032){ref-type="ref"}        1994                                                                                                                                                Moderate
  Meany[^25^](#cam43110-bib-0025){ref-type="ref"}          2007                                                                                                                                                Moderate
  Mullen[^40^](#cam43110-bib-0040){ref-type="ref"}         2018                                                                                                                                                Moderate
  Okuyama[^46^](#cam43110-bib-0046){ref-type="ref"}        2002                                                                                                                                                Moderate
  Owens[^47^](#cam43110-bib-0047){ref-type="ref"}          2016                                                                                                                                                Moderate
  Rojas[^42^](#cam43110-bib-0042){ref-type="ref"}          2014                                                                                                                                                Moderate
  Sirin[^48^](#cam43110-bib-0048){ref-type="ref"}          2016                                                                                                                                                Moderate
  Vaarwerk[^51^](#cam43110-bib-0051){ref-type="ref"}       2018                                                                                                                                                Moderate
  Vali[^59^](#cam43110-bib-0059){ref-type="ref"}           2015                                                                                                                                                Moderate
  Voss[^26^](#cam43110-bib-0026){ref-type="ref"}           2012                                                                                                                                                Serious
  Wickmann[^27^](#cam43110-bib-0027){ref-type="ref"}       2003                                                                                                                                                Serious
  Zanetta[^57^](#cam43110-bib-0057){ref-type="ref"}        1994                                                                                                                                                Serious
  White[^49^](#cam43110-bib-0049){ref-type="ref"}          1991                                                                                                                                                Moderate

Blue: no information; Green: low risk; Orange: moderate risk; Red: serious risk; Purple: critical risk.
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3.3. Analysis {#cam43110-sec-0015}
-------------

### 3.3.1. Lymphomas {#cam43110-sec-0016}

#### Non‐Hodgkin's lymphoma {#cam43110-sec-0017}

Four studies examined surveillance imaging in 110 patients with non‐Hodgkin's lymphoma.[^19^](#cam43110-bib-0019){ref-type="ref"}, [^20^](#cam43110-bib-0020){ref-type="ref"}, [^21^](#cam43110-bib-0021){ref-type="ref"}, [^22^](#cam43110-bib-0022){ref-type="ref"} Data from three of four studies indicated large numbers of scans, with 806 scan conducted in 66 patients.[^20^](#cam43110-bib-0020){ref-type="ref"}, [^21^](#cam43110-bib-0021){ref-type="ref"}, [^22^](#cam43110-bib-0022){ref-type="ref"} Where reported, scanning was associated with notable radiation dose (median whole body radiation dose of 40.3‐91.3 MSv).[^20^](#cam43110-bib-0020){ref-type="ref"}, [^21^](#cam43110-bib-0021){ref-type="ref"}

Three relapses occurred within one study population in a median time of 0.25 years. These were detected by symptoms.[^21^](#cam43110-bib-0021){ref-type="ref"} Surveillance imaging detected no relapse and produced 17 false positive images.[^19^](#cam43110-bib-0019){ref-type="ref"}, [^20^](#cam43110-bib-0020){ref-type="ref"}, [^22^](#cam43110-bib-0022){ref-type="ref"}

#### Hodgkin's lymphoma {#cam43110-sec-0018}

Five studies assessed surveillance imaging in 799 patients with Hodgkin's lymphoma.[^23^](#cam43110-bib-0023){ref-type="ref"}, [^24^](#cam43110-bib-0024){ref-type="ref"}, [^25^](#cam43110-bib-0025){ref-type="ref"}, [^26^](#cam43110-bib-0026){ref-type="ref"}, [^27^](#cam43110-bib-0027){ref-type="ref"} Surveillance programs comprised large numbers of images, where reported, 1293 in 291 patients.[^24^](#cam43110-bib-0024){ref-type="ref"}, [^25^](#cam43110-bib-0025){ref-type="ref"}, [^26^](#cam43110-bib-0026){ref-type="ref"}

Relapse was detected in 111 (13.8%) patients, 51 (45.9%) by surveillance imaging and 60 (45.1%) by clinical signs and symptoms. Thirty‐four false positive images were reported in two studies.[^24^](#cam43110-bib-0024){ref-type="ref"}, [^25^](#cam43110-bib-0025){ref-type="ref"}

One study reported a median time to relapse of 1.7 years by scan compared to 0.61 years in those detected by clinical signs and symptoms.[^26^](#cam43110-bib-0026){ref-type="ref"} For those relapses detected after 12 months off‐treatment, 5‐year survival after relapse was 100% for both groups.[^26^](#cam43110-bib-0026){ref-type="ref"} Another study reported 5‐year survival after relapse in those detected by surveillance imaging 64.6% ± 10.1% vs clinical signs and symptoms 73.8% ± 7.2% (*P* = .186).[^23^](#cam43110-bib-0023){ref-type="ref"}

### 3.3.2. Osteosarcoma {#cam43110-sec-0019}

Five studies of three cohorts reported on 247 patients with osteosarcoma.[^28^](#cam43110-bib-0028){ref-type="ref"}, [^29^](#cam43110-bib-0029){ref-type="ref"}, [^30^](#cam43110-bib-0030){ref-type="ref"}, [^31^](#cam43110-bib-0031){ref-type="ref"}, [^32^](#cam43110-bib-0032){ref-type="ref"} Where reported, the number of scans during surveillance programs was large, 2394 for 231 patients.[^28^](#cam43110-bib-0028){ref-type="ref"}, [^31^](#cam43110-bib-0031){ref-type="ref"}

Forty‐three patients experienced relapse, with one study providing comparative data on the numbers of patients who experienced relapse detected by surveillance imaging vs symptoms, 7/28 vs 21/28, respectively.[^28^](#cam43110-bib-0028){ref-type="ref"} Survival data were largely lacking. Korholz et al reported a 5‐year overall survival of 67%, without comparative data on the method of relapse detection.[^28^](#cam43110-bib-0028){ref-type="ref"}

### 3.3.3. Ewing's sarcoma {#cam43110-sec-0020}

Four studies of three cohorts of 355 patients with Ewing's sarcoma were reported.[^30^](#cam43110-bib-0030){ref-type="ref"}, [^33^](#cam43110-bib-0033){ref-type="ref"}, [^34^](#cam43110-bib-0034){ref-type="ref"}, [^35^](#cam43110-bib-0035){ref-type="ref"} About 181 patients relapsed, 87 (48.0%) of which were detected by surveillance imaging and 94 (52.0%) by clinical signs and symptoms.

One study reported a shorter median time to relapse, 0.28 vs 1.22 years, and a lower 5‐year survival, 0% vs 17%, in symptomatic patients compared to those detected by surveillance imaging.[^33^](#cam43110-bib-0033){ref-type="ref"} Another study also reported a shorter nonsignificant median time to relapse, 1.6 vs 1.9 years (*P* = .07), between symptomatic and surveillance detection.[^34^](#cam43110-bib-0034){ref-type="ref"} Another study found that 5‐year overall survival (OS) after relapse was higher in asymptomatic patients vs symptomatic patients, 37% vs 9%.[^35^](#cam43110-bib-0035){ref-type="ref"}

### 3.3.4. Wilms tumor {#cam43110-sec-0021}

Six studies explored five cohorts of 5074 patients with Wilms tumor.[^17^](#cam43110-bib-0017){ref-type="ref"}, [^36^](#cam43110-bib-0036){ref-type="ref"}, [^37^](#cam43110-bib-0037){ref-type="ref"}, [^38^](#cam43110-bib-0038){ref-type="ref"}, [^39^](#cam43110-bib-0039){ref-type="ref"}, [^40^](#cam43110-bib-0040){ref-type="ref"} These experienced 836 relapses; where method of relapse detection was reported, 501 were detected by surveillance imaging and 181 detected by symptoms. Not all patients had method of relapse detection reported.

Three of the cohorts contributed few data, with \< 20 relapses per study.[^37^](#cam43110-bib-0037){ref-type="ref"}, [^38^](#cam43110-bib-0038){ref-type="ref"}, [^39^](#cam43110-bib-0039){ref-type="ref"} From the two larger cohorts, 5‐year OS after relapse was 56% and 67%.[^36^](#cam43110-bib-0036){ref-type="ref"}, [^40^](#cam43110-bib-0040){ref-type="ref"} Overall survival for those detected by surveillance vs symptoms was 70% (95% CI, 63% to 77%) vs 59% (95% CI, 46% to 72%).[^40^](#cam43110-bib-0040){ref-type="ref"} One study reported a lower median duration of survival after relapse for patients detected by symptoms (22 months with symptoms, not reached for asymptomatic, hazard ratio 1.84 (95% CI 1.24‐2.74)).[^36^](#cam43110-bib-0036){ref-type="ref"}

Other relevant outcomes included the number of scans to detect one subclinical relapse of 112 (95% CI 106‐119) during the first 2 years after nephrectomy and 500 (95% CI 416‐588) 2‐5 years after nephrectomy and a cost for follow‐up studies of \$347,968 per patient.[^36^](#cam43110-bib-0036){ref-type="ref"}, [^37^](#cam43110-bib-0037){ref-type="ref"}

### 3.3.5. Hepatoblastoma {#cam43110-sec-0022}

There were 73 patients with hepatoblastoma included in three studies.[^17^](#cam43110-bib-0017){ref-type="ref"}, [^41^](#cam43110-bib-0041){ref-type="ref"}, [^42^](#cam43110-bib-0042){ref-type="ref"} In two studies, 5/42 patients relapsed, all detected by rise in alpha‐fetoprotein (AFP) levels rather than imaging.[^17^](#cam43110-bib-0017){ref-type="ref"}, [^42^](#cam43110-bib-0042){ref-type="ref"} One study did not report the number of patients relapsed but stated that all were detected by rise in AFP levels prior to imaging.[^41^](#cam43110-bib-0041){ref-type="ref"}

In total, 408 imaging studies were performed, although two studies only reported CT data without other imaging types. No study reported data on overall survival. One study found no significant difference in time to relapse between patients detected by surveillance and those detected by symptoms.[^42^](#cam43110-bib-0042){ref-type="ref"}

### 3.3.6. Neuroblastoma {#cam43110-sec-0023}

Five studies described 487 patients with neuroblastoma, mostly high‐risk disease, of whom 272 relapsed.[^43^](#cam43110-bib-0043){ref-type="ref"}, [^44^](#cam43110-bib-0044){ref-type="ref"}, [^45^](#cam43110-bib-0045){ref-type="ref"}, [^46^](#cam43110-bib-0046){ref-type="ref"}, [^47^](#cam43110-bib-0047){ref-type="ref"} Where reported, 149 were detected by surveillance imaging and 82 by symptoms.

Survival statistics were variably reported, with most studies reporting less than 5‐year follow‐up. Few patients survived following relapse (n = 2 in CR, three alive with disease of 28 relapses).[^43^](#cam43110-bib-0043){ref-type="ref"}, [^44^](#cam43110-bib-0044){ref-type="ref"}, [^46^](#cam43110-bib-0046){ref-type="ref"} Curve‐estimated 5‐year overall survival after relapse is around 3% in those detected by surveillance and 0% in those detected by symptoms.[^45^](#cam43110-bib-0045){ref-type="ref"}

One study reported a mean of 29.5 CT scans per patient and another reported a median of 35 images (median CED 133.5 mSv) from the time of initial diagnosis to relapse.[^44^](#cam43110-bib-0044){ref-type="ref"}, [^47^](#cam43110-bib-0047){ref-type="ref"}

### 3.3.7. Retinoblastoma {#cam43110-sec-0024}

Two studies assessed 65 patients with retinoblastoma.[^48^](#cam43110-bib-0048){ref-type="ref"}, [^49^](#cam43110-bib-0049){ref-type="ref"} Three patients relapsed, one was detected by surveillance imaging and two by symptoms. A total of 223 scans were conducted and 11 false positive images were reported. Survival data are lacking.

### 3.3.8. Soft tissue sarcomas {#cam43110-sec-0025}

Four studies examined rhabdomyosarcoma and included 466 patients with 325 relapses.[^3^](#cam43110-bib-0003){ref-type="ref"}, [^50^](#cam43110-bib-0050){ref-type="ref"}, [^51^](#cam43110-bib-0051){ref-type="ref"}, [^52^](#cam43110-bib-0052){ref-type="ref"} One study included all pediatric soft tissue sarcomas---235 patients with relapsed disease, of whom 150 had rhabdomyosarcoma.[^16^](#cam43110-bib-0016){ref-type="ref"}

In the studies that only included patients with rhabdomyosarcoma, where method of detection was reported, 85 relapses were detected by surveillance imaging and 140 by symptoms. In Dantonello et al, 90 were detected by surveillance, and 139 by symptoms. One study reported 507 scans in 40 patients, with scanning frequency data not provided by other studies.[^50^](#cam43110-bib-0050){ref-type="ref"}

Two studies reported survival data.[^3^](#cam43110-bib-0003){ref-type="ref"}, [^51^](#cam43110-bib-0051){ref-type="ref"} Neither found a significant difference in overall survival between those detected by surveillance and by symptoms. The survival rate was lower in one study compared to the other (surveillance vs symptoms: 20% vs 11% 3‐year survival and 43.3% vs 44.6% 5‐year survival, respectively), as the former included progression of disease along with relapse. [^3^](#cam43110-bib-0003){ref-type="ref"}, [^51^](#cam43110-bib-0051){ref-type="ref"}

In Dantonello et al, 5‐year overall survival from primary surgery was 40% for those detected by surveillance and 29% for those detected by symptoms.[^16^](#cam43110-bib-0016){ref-type="ref"} However, by 10 years, survival was 21% for surveillance and 23% for symptomatic. These differences may reflect different biology of disease being detected by surveillance, with these patients surviving longer.

### 3.3.9. Other tumors {#cam43110-sec-0026}

Eight studies examined 583 patients with unique pediatric malignancies, see Table [1](#cam43110-tbl-0001){ref-type="table"} for details.[^53^](#cam43110-bib-0053){ref-type="ref"}, [^54^](#cam43110-bib-0054){ref-type="ref"}, [^55^](#cam43110-bib-0055){ref-type="ref"}, [^56^](#cam43110-bib-0056){ref-type="ref"}, [^57^](#cam43110-bib-0057){ref-type="ref"}, [^58^](#cam43110-bib-0058){ref-type="ref"}, [^59^](#cam43110-bib-0059){ref-type="ref"}, [^60^](#cam43110-bib-0060){ref-type="ref"} These studies were generally small, all including less than 70 patients, except for Geldart et al who included 329 patients. No study reported more than 20 relapses. Overall survival was reported in four studies.[^53^](#cam43110-bib-0053){ref-type="ref"}, [^56^](#cam43110-bib-0056){ref-type="ref"}, [^57^](#cam43110-bib-0057){ref-type="ref"}, [^58^](#cam43110-bib-0058){ref-type="ref"} No study reported differences in survival between groups based on method of relapse detection.

4. DISCUSSION {#cam43110-sec-0027}
=============

Evidence on the use of surveillance imaging in pediatric extracranial solid tumors is derived exclusively from observational studies. Surveillance strategies are often poorly reported and variable in design, making replication of many studies impossible. The risk of bias for most studies is significant. Evidence gaps were present in all malignancies and the quality of studies was generally low, with particular issues around confounding and lead‐time bias. Conclusive statements regarding the survival benefit of surveillance imaging cannot be made based on information identified in this review.

We recognize that reporting combinations of different imaging types together makes it challenging to separate out the roles of each modality for different malignancies. Sadly, much of the available literature includes all imaging types and presenting separate findings is currently impossible.

Notwithstanding these limitations, it is possible to establish that surveillance imaging programs result in large number of additional imaging investigations, often associated with notable radiation doses. There is a risk of false positive images, including incidental or uncertain findings, which was particularly present in studies of lymphoma. These may be associated with additional distress for patients and families, as well as further investigations. Even with large numbers of tests, surveillance imaging detected only 57% of relapses identified.

Survival outcomes were generally poorly reported. For most malignancies studied, the data available suggested no significant difference in survival between patients whose relapse was detected by surveillance and those whose relapse was detected by symptoms. One exception to this finding is within Wilms tumor, where detection by surveillance imaging does appear consistent with increased survival. However, the number needed to scan is large and the financial costs of surveillance imaging are high. Summary information with the clinical bottom line for each cancer type is provided in Box [2](#cam43110-fea-0002){ref-type="boxed-text"}.

###### Clinical bottom lines

 {#cam43110-sec-0028}

*Lymphomas*

. Large numbers of scans and false positive imaging is demonstrated in the literature. More research is needed on whether surveillance imaging provides survival benefit.

*Osteosarcoma*

Large numbers of scans are conducted. A lack of comparative survival data between relapses detected by surveillance vs. symptoms. More research is needed on whether surveillance imaging provides survival benefit.

*Ewing's sarcoma*

Surveillance imaging may not detect relapse prior to symptoms. Those detected earlier by symptoms may have more aggressive disease and therefore have a lower survival after relapse. Research using appropriate effect measures is needed to infer a survival benefit.

*Wilm's tumour*

Most relapses were detected by surveillance imaging and this appears consistent with increased survival. Data on survival benefit was reported post relapse and at risk of lead‐time bias, thus should be interpreted with caution. The number needed to scan is large and the financial costs are high.

*Hepatoblastoma*

Tumour markers detected all relapses in the literature prior to surveillance imaging, though there were few relapses reported. Patients received a large number of imaging studies. There is no evidence on the effect of surveillance imaging on survival.

*Neuroblastoma*

Evidence was derived mostly from high‐risk patients. The risk of relapse was high and few patients with relapse survived, regardless of the method of detection. Surveillance programmes involved a large number of scans and a significant radiation dose.

*Retinoblastoma*

Large numbers of scans were conducted and were associated with false positive images. There is no evidence on the effect of surveillance imaging on the time to detection of relapse or on survival.

*Soft tissue sarcoma*

Numbers of scans were high and most relapses were detected by symptoms. Evidence does not support improved survival after relapse of rhabdomyosarcoma in those detected by surveillance imaging. For patients with other soft tissue sarcomas evidence is inconclusive.

*Other tumours*

Minimal data is available on the impact of surveillance in rarer diseases and no evidence suggests improved survival with surveillance.

It is important to recognize that any differences in survival reported in these nonrandomized studies may be due to the variable biology of relapsed disease rather than an effect of surveillance. As such, randomized studies are necessary in order to truly evaluate the role of routine surveillance imaging in pediatric patients with extracranial solid tumors.

No qualitative data, psychological distress indicator studies, or studies exploring morbidity or burden of relapse treatment, including the risk of secondary malignancies, were identified. As such, the literature captures little of the patient's or family's experience of routine surveillance programs, which may be positive, negative, or both, or of the subsequent treatment of relapse. This is particularly disappointing given our PPI group stressed the importance of these issues. They highlighted to us the importance of understanding the "sawtooth" of anxiety relating to scanning ("scanxiety"), where the anxiety builds to the point of receiving the results of a scan, followed by the relief of a result showing no evidence of disease. They discussed that there may be different anxieties experienced if routine surveillance imaging was not undertaken. They also felt the literature should reflect that knowing about a relapse in advance may not change survival but may alter how life was lived, and thus a deeper exploration of the meanings surrounding surveillance imaging would be a key contribution to the literature in the future. We strongly recommend that high‐quality qualitative research should be performed to understand the various roles of follow‐up, the meaning assigned to surveillance imaging, and the preferences of patients, parents, and professionals in this setting. This research should include both those undergoing routine disease surveillance and those who are not.

The strengths of this review lie in the robust systematic review methodology, informed by extensive PPI engagement focused on design, interpretation, and dissemination. One key challenge lies in how to address teenage and young adult malignancies in systematic reviews. We excluded studies where the majority of participants were over 25. For some diseases, where the population prevalence straddles this cutoff (eg, Hodgkin's lymphoma and germ cell tumors), this review does not provide all relevant data. Future reviews of these particular malignancies should focus on surveillance across the population.

In addition to this, it is important to recognize that there are challenges in identifying whether patients are symptomatic at the time of surveillance imaging, particularly in retrospective studies. Even if this was identified, this was rarely reported within the literature. We recognize that some patients may have presented with symptoms at the point of surveillance and may have therefore been classified either as symptomatic or detected by surveillance. The effects of this within the data are difficult to predict. It is possible that studies could have consistently classified these patients as one mode of detection over the other. If, for example, patients were more frequently classified as detected by surveillance, it may appear that surveillance images identify more relapses than would be the case in practice. However, it is unlikely to change the duration of survival findings if patients are symptomatic at surveillance visits. Future prospective studies should aim to capture this information so as to inform our understanding of the role of surveillance imaging in this setting.

Concerted effort is required to improve understanding of the risks and benefits of surveillance imaging. We strongly recommend the review of currently held data from research trials or cohorts not currently in the public domain. This may include combining data from multiple studies to inform the research problem. We also recommend the national and international trial bodies to consider including the randomization of follow‐up policies within future trial platforms so as to provide further information about best surveillance practices. Furthermore, we recognize that surveillance imaging programs should change over time, as both up‐front and relapse therapies change, and as the imaging modalities available for surveillance develop, resulting in a different balance of risks and benefits for patients.

5. CONCLUSIONS {#cam43110-sec-0029}
==============

At present, there is insufficient evidence to evaluate the effects of routine surveillance imaging on survival in most pediatric extracranial solid tumors. More high‐quality focused research is needed that uses appropriate effect measures to address the research questions, alongside well‐conducted qualitative data. This should be a key research priority considering the substantial impact of imaging on patient experience, and the financial and opportunity costs to health services.
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